What is extraskeletal myxoid chondrosarcoma?
Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft-tissue sarcoma that usually grows deep in the muscles of the thigh, hip or shoulder. It makes up less than 3% of soft-tissue sarcomas.
Despite its name, EMC is not a true cartilage cancer. The word “chondrosarcoma” comes from its jelly-like (myxoid) appearance, which once made pathologists think it formed cartilage. Modern studies show that it is a separate disease. The World Health Organization (WHO) lists it among soft-tissue tumours of uncertain differentiation, which means the normal cell it comes from is still unknown.
EMC is defined by a gene fusion involving the NR4A3 gene. Most often, NR4A3 is joined to a gene called EWSR1. Finding this fusion confirms the diagnosis (Stacchiotti et al., 2020).
EMC typically affects adults in their 40s to 60s and is about twice as common in men as in women. It tends to grow slowly over many years.
Slow growth does not mean it is harmless. EMC often comes back after surgery and can spread to the lungs, sometimes many years after the first treatment (Meis-Kindblom et al., 1999). Many people still live for a long time, even with spread.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Soft-tissue sarcoma of uncertain differentiation |
| How common | Rare; under 3% of soft-tissue sarcomas |
| Typical age | Most 40-65 years; median about 50 |
| Sex | About twice as common in men |
| Common sites | Thigh, hip and buttock, shoulder, trunk |
| Hallmark gene change | NR4A3 fusion, most often EWSR1::NR4A3 |
| Main treatment | Wide surgical removal, often with radiotherapy |
| Typical spread | Lungs most often; also lymph nodes, bone, soft tissue |
| Outlook | Long survival is common, but recurrence and late spread are frequent |
2. Causes and risk factors
The cause of EMC is not known. There are no proven lifestyle or environmental risk factors, and it is not inherited.
The gene fusion behind EMC
In EMC, a piece of chromosome 9 carrying the NR4A3 gene breaks off and joins another gene. This creates an abnormal “fusion” protein that switches on genes that drive tumour growth.
| Fusion partner | How often | Notes |
|---|---|---|
| EWSR1::NR4A3 | About 60-75% | The classic form |
| TAF15::NR4A3 | About 15-25% | May be linked with a higher-grade appearance and poorer outlook (Huang et al., 2023) |
| TCF12, TFG, HSPA8 and others | Rare | Found in a small number of tumours |
These changes arise only in the tumour cells during a person’s lifetime. They are not passed on to children.
What does not cause EMC
- It is not caused by an injury, although a knock often draws attention to a lump that was already there
- It is not linked to diet or smoking
- It does not develop from benign cartilage tumours or from bone chondrosarcoma
3. How does it look
The lump
| Feature | Description |
|---|---|
| Location | Usually deep within muscle, most often in the thigh or around the hip |
| Size | Often large at diagnosis, with many over 5 cm and some over 10 cm |
| Feel | Firm or rubbery, sometimes soft |
| Mobility | Often fixed to deeper structures |
| Skin | Usually normal over the lump |
| Growth | Slow, over months or years |
On scans
| Feature | MRI appearance |
|---|---|
| Shape | Lobulated (multi-lobed), well-defined mass |
| T2-weighted images | Very bright, because of the watery myxoid material |
| T1-weighted images | Low to intermediate signal; bright spots if there has been bleeding |
| Internal structure | Thin dividing walls (septa) between lobules |
| After contrast dye | Enhancement of the septa and the edges of lobules |
| Bleeding | Areas of old bleeding are common |
The bright, lobulated look can resemble a cyst or a benign myxoid tumour, which is one reason why a biopsy at a sarcoma centre is important.
Under the microscope
| Feature | Description |
|---|---|
| Pattern | Many lobules separated by fibrous bands |
| Background | Abundant pale blue-grey myxoid (jelly-like) material |
| Cells | Small, uniform, oval to spindle-shaped cells with pink cytoplasm |
| Arrangement | Cords, strands and lace-like networks |
| Bleeding | Frequent haemorrhage within the tumour |
| Cellular variant | Some tumours have sheets of cells and little myxoid material; these may behave more aggressively |
| Special stains | Often positive for INSM1; S100 positive in a minority; keratin usually negative |
| Molecular test | FISH or sequencing to find the NR4A3 fusion |
4. Symptoms
EMC often causes few symptoms for a long time. Many people notice the lump only when it is already large.
Common symptoms
- A painless lump or swelling, usually in the thigh, hip, buttock or shoulder
- A lump that has been slowly growing over months or years
- Aching or discomfort, especially if the tumour presses on nerves or muscles
- Stiffness or reduced movement of a nearby joint
- Sudden swelling or pain if there is bleeding inside the tumour
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Lungs | Often no symptoms at first; later cough, breathlessness or chest pain |
| Lymph nodes | Swollen lumps in the groin or armpit (uncommon) |
| Bone | Bone pain |
| Soft tissue elsewhere | New lumps under the skin or in muscle |
When to seek medical advice
See a doctor about any lump that is:
- Larger than 5 cm (about the size of a golf ball)
- Growing
- Deep below the muscle layer
- Painful, or a lump that has come back after being removed
These are warning signs for sarcoma, and such lumps should be checked with imaging and referred to a specialist sarcoma centre (Gronchi et al., 2021).
5. Diagnosis
| Test | Purpose |
|---|---|
| Clinical examination | Assesses size, depth and mobility of the lump |
| Ultrasound | First quick look at a soft-tissue lump |
| MRI | Shows the tumour’s extent and its relationship to nerves and blood vessels |
| Core needle biopsy | Takes tissue samples; should be planned by the sarcoma team |
| Pathology and molecular testing | Confirms EMC by finding the NR4A3 fusion |
| CT scan of the chest | Checks the lungs, the most common site of spread |
| Other scans | PET-CT or whole-body MRI in selected cases |
The biopsy route should be chosen so that it can be removed during the later operation. A poorly placed biopsy can spread tumour cells and make surgery harder, which is why ESMO guidelines advise that it is done at, or in contact with, a sarcoma reference centre (Gronchi et al., 2021).
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Myxoma | Benign; very few cells; no NR4A3 fusion |
| Myxoid liposarcoma | Has fat cells and a different fusion (FUS::DDIT3) |
| Myxofibrosarcoma | Usually older people; often near the skin surface; no NR4A3 fusion |
| Low-grade fibromyxoid sarcoma | Different fusion (FUS::CREB3L2); MUC4 positive |
| Myoepithelial tumours | Keratin and other epithelial markers often positive |
| Bone chondrosarcoma | Arises in bone and forms true cartilage |
6. Treatment
Treatment is planned by a multidisciplinary sarcoma team, including surgeons, radiation and medical oncologists, radiologists and pathologists.
Surgery
Surgery is the main treatment for EMC that has not spread.
| Approach | Notes |
|---|---|
| Wide local excision | Removes the tumour with a layer of healthy tissue all around it |
| Limb-sparing surgery | Possible for most people; amputation is rarely needed |
| Reconstruction | Muscle flaps or grafts may be used to fill large defects |
| Re-excision | Considered if the first operation left tumour at the edges |
Achieving clear margins is the most important step in reducing the risk of the tumour coming back.
Radiotherapy
Radiotherapy is often used together with surgery:
- Before surgery, to shrink the tumour and make clear margins easier to achieve
- After surgery, especially for large or deep tumours or close margins
- For tumours that cannot be removed
- To relieve symptoms from metastases, such as bone pain
Treatment of advanced disease
EMC responds poorly to standard chemotherapy. Doxorubicin-based treatment shrinks only a small number of tumours (Stacchiotti et al., 2020).
| Option | Notes |
|---|---|
| Pazopanib | In a phase 2 trial, most tumours stopped growing and some shrank (Stacchiotti et al., 2019) |
| Sunitinib | Produced responses in a small series of patients (Stacchiotti et al., 2014) |
| Other targeted drugs | Further drugs that block blood vessel growth signals are being studied |
| Surgery for lung metastases | Removing a small number of lung nodules can be worthwhile because the disease often grows slowly |
| Radiotherapy or ablation | For individual metastases |
| Active surveillance | Slow-growing, symptom-free metastases may be monitored before starting treatment |
| Clinical trials | Recommended where available |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Radiotherapy before surgery | Short daily sessions on weekdays over about 5 weeks; surgery follows a few weeks later |
| The operation | General anaesthetic and a hospital stay of a few days to a week, depending on the size and site |
| Wound care | Drains and dressings at first; wound problems are more common after pre-operative radiotherapy |
| Physiotherapy | Starts soon after surgery to rebuild strength and movement |
| Return to normal life | Many people return to work and daily activities within a few months |
| Tablets for advanced disease | Pazopanib or sunitinib are taken at home, with regular blood pressure and blood tests |
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, wound problems, weakness, reduced movement, swelling of the limb |
| Radiotherapy | Skin redness, tiredness, wound healing problems (especially before surgery), later stiffness or swelling |
| Pazopanib or sunitinib | High blood pressure, diarrhoea, tiredness, liver test changes, hair colour change, sore hands and feet |
7. Outlook (prognosis)
EMC usually behaves as a slow but persistent cancer.
| Measure | Approximate figures |
|---|---|
| Survival at 5 years | About 80-90% |
| Survival at 10 years | About 65-70% |
| Local recurrence | Up to about 1 in 3 to 1 in 2 in older series, often years later |
| Distant spread | About 1 in 3 to 1 in 2 over time, mainly to the lungs |
In the largest early study, of 117 people, survival was about 90% at 5 years and 70% at 10 years (Meis-Kindblom et al., 1999). A later study from two referral centres also reported long survival, even in people with metastases (Drilon et al., 2008).
Factors linked with a poorer outlook
- Large tumour size, especially over 10 cm
- Older age
- Spread at diagnosis
- Tumour location near the trunk rather than the limbs
- Cellular, high-grade appearance under the microscope
- Possibly the TAF15::NR4A3 fusion
A large registry-based analysis confirmed that most people survive for many years, with tumour size and spread at diagnosis being the strongest influences on survival (Brown et al., 2022).
Because the cancer can return 10 years or more after treatment, long-term follow-up is essential.
8. Follow-up
| Follow-up | Typical schedule |
|---|---|
| Clinical examination | Every 3-6 months for the first 2-3 years, then every 6-12 months |
| MRI of the original site | To detect local recurrence |
| Chest CT | To detect lung metastases |
| Long-term follow-up | Continued for 10 years or longer because late recurrences are common |
9. Living with extraskeletal myxoid chondrosarcoma
- Attend all follow-up scans, even many years after treatment
- Report any new lump, swelling or persistent cough
- Physiotherapy helps restore strength and movement after surgery
- Manage limb swelling with exercise, compression garments and skin care
- Look after your general health with regular activity, a balanced diet and no smoking
- Seek support from sarcoma charities and patient groups; rare cancers can feel isolating
- Ask about psychological support if worry about recurrence affects daily life
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is EMC a bone cancer? | No. Despite the name, it arises in soft tissues and does not form true cartilage |
| Is it inherited? | No. The gene fusion occurs only in the tumour |
| Will I need chemotherapy? | Usually not; standard chemotherapy works poorly for EMC |
| Can I live a long time with EMC? | Yes. Many people live for many years, even with lung metastases |
| Why is follow-up so long? | Because EMC can come back 10 years or more after treatment |
| Can EMC occur in children? | Very rarely; it is mainly a disease of adults |
| Should I be treated at a sarcoma centre? | Yes. Treatment at an experienced centre improves the quality of surgery and care |
11. Questions to ask your care team
- Has the NR4A3 fusion been confirmed, and which partner gene is involved?
- Were the surgical margins clear?
- Do I need radiotherapy, and should it be before or after surgery?
- How often will I have scans, and for how long?
- What are the options if the cancer spreads to the lungs?
- Are there clinical trials suitable for me?
Resources
- Brown, J.M. et al. (2022) ‘Extraskeletal myxoid chondrosarcoma: clinical features and overall survival’, Cancer Treatment and Research Communications, 31, 100530.
- Drilon, A.D. et al. (2008) ‘Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy’, Cancer, 113(12), pp. 3364-3371.
- Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
- Huang, S.C. et al. (2023) ‘Extraskeletal myxoid chondrosarcomas: the uncommon clinicopathologic manifestations and significance of TAF15::NR4A3 fusion’, Modern Pathology, 36(7), 100161.
- Meis-Kindblom, J.M. et al. (1999) ‘Extraskeletal myxoid chondrosarcoma: a reappraisal of its morphologic spectrum and prognostic factors based on 117 cases’, American Journal of Surgical Pathology, 23(6), pp. 636-650.
- Stacchiotti, S. et al. (2014) ‘Activity of sunitinib in extraskeletal myxoid chondrosarcoma’, European Journal of Cancer, 50(9), pp. 1657-1664.
- Stacchiotti, S. et al. (2019) ‘Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial’, Lancet Oncology, 20(9), pp. 1252-1262.
- Stacchiotti, S. et al. (2020) ‘Extraskeletal myxoid chondrosarcoma: state of the art and current research on biology and clinical management’, Cancers, 12(9), 2703.
- National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.